Coinspeaker NVAX Stock Up 13%, Novavax Early Trial of COVID-19 Vaccine Shows Stellar Immune ResponseScientists have Novavax's vaccine results to be impressive and exemplary. If the company gets more leads going ahead, it promises of producing 100 million doses by the start of 2021. origin »
Coinspeaker NVAX Stock Up Nearly 16% in Pre-market as Novavax Starts Coronavirus Vaccine TrialsNovavax (NVAX) has jumped by 16% in the pre-market. The company has announced human trials its COVID-19 vaccine.
Coinspeaker NVAX Stock Jumped 25% Yesterday, Down 15% Now as Novavax Works on COVID-19 VaccineNovavax (NVAX) stock climbed 25% yesterday, adding to its current 2020 gains, as the company makes progress on its COVID-19 vaccine candidate.
Coinspeaker Coronavirus Stocks: Why Gilead Sciences, Moderna, Inovio Pharmaceuticals, Novavax RoseWhile tech shares are suffering drops, coronavirus stocks are soaring, The pharma companies are actively working on the development of a new vaccine.